Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an update.
RemeGen Co., Ltd. has announced a board meeting scheduled for August 22, 2025, to review and approve the interim financial results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market position and stakeholder interests.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of innovative therapies, primarily targeting unmet medical needs in oncology and autoimmune diseases.
Average Trading Volume: 11,729,185
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.92B
Learn more about 9995 stock on TipRanks’ Stock Analysis page.